DOES BLOCKING PROINFLAMMATORY CYTOKINES DIMINISH CANCER-RELATED FATIGUE?

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标 这项研究的主要目的是使用细胞因子拮抗剂英夫利昔单抗(Remicade)，从实验上探索促炎细胞因子和疲劳之间的联系。英夫利昔单抗被FDA批准用于治疗类风湿性关节炎和其他炎症性疾病，并已被证明可以减少这些患者的促炎细胞因子和行为障碍。这项第二阶段的初步研究将评估对患有持续性疲劳的乳腺癌幸存者使用英夫利昔单抗的可行性，并确定英夫利昔单抗对促炎细胞因子、疲劳和其他行为症状的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS The primary goal of this study is to experimentally probe the association between proinflammatory cytokines and fatigue using a cytokine antagonist, infliximab (Remicade). Infliximab is FDA approved for treatment of rheumatoid arthritis and other inflammatory conditions and has been shown to reduce proinflammatory cytokines and behavioral disturbances in these patients. This Phase II pilot study will evaluate the feasibility of administering infliximab to breast cancer survivors with persistent fatigue and determine the effects of infliximab on proinflammatory cytokines, fatigue, and other behavioral symptoms.